Advanced Disease (Phase I) Cancer Studies Currently Recruiting Participants at the University of Chicago Comprehensive Cancer Center

Study Number Title
16830A Communication Preferences, Expectations of Benefit, and Symptom Burdens Among Advanced Cancer Patients and Partners During Patient Participation in Phase I Trials
Select
10-487-A The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
Select
11-0514 A Phase 1 2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary AntiTumor Activity of the Oral ALK EGFR Inhibitor AP26113
Select
12-1169 A pharmacodynamic study of sirolimus in older children and adults with advanced solid malignancies
Select
12-1318 A Drug-Drug Interaction Study of Capecitabine and Celecoxib in Patients with Advanced Solid Malignancies
Select
12-1667 A Phase I Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-KIR (BMS-986015) Administered in Combination with Anti-PD-1 (BMS-936558) in Advanced Refractory Solid Tumors
13-0002 A Registry for Serial Imaging and Plasma Assessment in Advanced Solid Tumor Patients
Select
13-0171 A Phase I Open-Label Dose Escalation Study With Expansion To Assess The Safety And Tolerability Of INC280 In Patients With c-MET Dependent Advanced Solid Tumors
IRB13-0614 A Pharmacodynamic Study of Sirolimus and Metformin in Patients with Advanced Solid Tumors
Select
IRB13-0705 Phase I, Single-Center, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Preliminary Antineoplastic Activity of OTS167, a MELK Inhibitor, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies
Select
IRB13-0816 An Open-Label Study to Determine the Maximum Tolerated Dose of CEP-37440 Administered as a Single Agent in Patients with Advanced or Metastatic Solid Tumors
Select
IRB13-0936 A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
Select
IRB13-1013 A Phase 1b, Open Label, Dose Escalation Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of Axitinib (AG-013736) in Combination With Crizotinib (PF-02341066) in Patients With Advanced Solid Tumors
Select
IRB13-1115 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Subjects with Advanced Solid Tumors
IRB13-0707 A Registry of Prospective Tumor Biomarker-Based Treatment Decisions for Advanced Solid Tumors
Select
IRB13-1443 Phase 1, Open-Label Study to Assess the Safety and Tolerability of DS-8273a in Subjects with Advanced Solid Tumors or Lymphomas

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.